Adocia Completes €9.7 Million Private Placement

Adocia, a biopharmaceutical company, announced the completion of a €9.7 million private placement. This was achieved through the issuance of 2,125,000 new ordinary shares, each with an attached share warrant. Maxim Group LLC and All Invest acted as placement agents for this transaction.

The new shares, admitted to trading alongside existing shares, bear the ISIN code FR0011184241-ADOC. The attached warrants are immediately detached and listed under ISIN code FR001400XVZ4.

Following this placement, Adocia's share capital has adjusted. The breakdown is now significantly impacted by financial investors owning 25.2% (non-diluted) and 30.0% (diluted). The Soula family retains a notable stake, holding 9.3% of the capital.

The company, based in Lyon, focuses on innovative treatments for diabetes and obesity. It boasts technology platforms like BioChaperone® and AdOral® for drug development.